Climb Bio Q2 FY26 net loss widens 55.73% to $13.5 million - CLYM News | RalliesClimb Bio Q2 FY26 net loss widens 55.73% to $13.5 million
C
CLYM• Clinical pipeline update
- CLYM116 Phase 1 PK/PD data are due at an R&D Spotlight on Sept. 3; Phase 2 IgA nephropathy dosing is expected to start in Q3 2026.
Quarterly results and cash position
- Climb Bio posted a GAAP net loss of $13.5 million, widening from $8.67 million a year earlier.
- R&D expense rose to $9.71 million from $6.58 million; G&A expense increased to $5.65 million from $4.1 million.
- Cash, cash equivalents, and marketable securities climbed to $239.22 million as of June 30, 2026, from $160.65 million at end-2025.
- Private placement financing generated about $110 million in gross proceeds, extending cash runway into the second half of 2028.
